Sather Financial Group Inc Abb Vie Inc. Transaction History

Sather Financial Group Inc

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 07, 2024	SELL	$159.82 - $182.1 $9.08 Million - $10.3 Million	-56,790 Reduced 95.35%	2,769 $504,000
Q4 2023 Jan 26, 2024	BUY	$137.6 - $154.97 $21,465 - $24,175	156 Added 0.26%	59,559 $9.23 Million
Q3 2023 Oct 19, 2023	BUY	$133.59 - $154.65 $81,890 - $94,800	613 Added 1.04%	59,403 $8.85 Million
Q4 2022 Jan 20, 2023	BUY	$138.31 - $165.87 $7.85 Million - $9.42 Million	56,777 Added 2820.52%	58,790 $0
Q3 2022 Oct 21, 2022	BUY	$134.21 - $153.93 $1,744 - $2,001	13 Added 0.65%	2,013 $270,000
Q1 2022 Apr 29, 2022	BUY	$131.98 - $163.75 $263,960 - $327,500	2,000 New	2,000 $324,000
Q1 2020 May 11, 2020	SELL	$64.5 - $97.79 $224,524 - $340,406	-3,481 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$72.13 - $90.25 $27,481 - $34,385	381 Added 12.29%	3,481 $308,000
Q3 2018 Nov 07, 2018	SELL	$88.91 - $98.84 $266,730 - $296,520	-3,000 Reduced 49.18%	3,100 $293,000
Q2 2018 Aug 03, 2018	BUY	$89.78 - $106.23 $8,978 - $10,623	100 Added 1.67%	6,100 $565,000
Q2 2017 Aug 15, 2017	BUY	N/A	6,000	6,000 $435,000

3,699

1.27B

13M

9.79M

Ticker ABBV
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,768,099,968
Market Cap $342B
Description
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...

Get notified when there are updates to the investment portfolio of Sather Financial Group Inc, based on Form 13F filings with the SEC.

Stay updated on Sather Financial Group Inc with notifications on news.